Your trusted source for investing success

Tag: diagnostics companies

Immortagen Completes Series A Financing for Personalized Medicine

Immortagen, Inc. announced that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen’s product pipeline fills

Enter Your Log In Credentials

Privacy & Legal Policy

Privacy Policy

Investing News Network